Gene · 117189
GRDX: Graves disease, susceptibility to, X-linked
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. GRDX: Graves disease, susceptibility to, X-linked. Genes, record 117189. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/117189
On this page
Gene
- Symbol
- GRDX
- Name
- Graves disease, susceptibility to, X-linked
- NCBI Gene ID
- 117189
- Aliases
- GD3
- Type
- unknown
Source NCBI Gene
Proteins0
Reviewed human proteins whose Swiss-Prot entry states the gene.
None in this release.
Patents0
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
None in this release.
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants731
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | GRDX papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 33 | 2025 |
| P50AA011999 | Southern California Research Center for ALPD and Cirrhosis | 7 | 2025 |
| ZIABC011055 | Serum Antibody Profiling with a Carbohydrate Microarray | 4 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 3 | 2025 |
| R01CA227942 | Targeting the cancer glycocalyx | 3 | 2025 |
| R35GM131686 | Investigation of Glycosylphosphatidylinositol (GPI) Anchorage and GPI-Anchored Proteins | 3 | 2025 |
| T32AI100853 | Training Program in Immunology and Inflammation | 3 | 2025 |
| ZIAHG200336 | Genetic and clinical studies of Gaucher disease and other lysosomal disorders | 3 | 2025 |
1 to 10 of 731Source NIH's project files
See all 731 nih grantsPapers1,950
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Effect of CaCl2 on the Structure of DODAB Vesicles Containing the Ganglioside GD3. | ACS Omega | 2026 | 42819183 | PubTator, text mining | PubMed |
| α2-3-sialylated glycosphingolipids in neuroinflammation, immunity, and programmed cell death: mechanistic evidence and context-dependent regulation: a comprehensive review. | Front Immunol | 2026 | 42688484 | PubTator, text mining | PubMed |
| Gangliosides GM3 and GD3 modulate insulin aggregation pathways and reduce cytotoxicity through structural remodeling. | Int J Biol Macromol | 2026 | 42665140 | PubTator, text mining | PubMed |
| Ganglioside Expression in Melanocytes: Modulation by Intrinsic and Extrinsic Factors. | Methods Mol Biol | 2026 | 42613539 | PubTator, text mining | PubMed |
| Long-Term Outcomes of Enzyme Replacement Therapy in Indian Patients with Gaucher Disease - A Multicentric Study. | Indian J Pediatr | 2026 | 42414749 | PubTator, text mining | PubMed |
| Losartan shows limited benefit in preclinical models of Geleophysic dysplasia. | Sci Rep | 2026 | 42332008 | PubTator, text mining | PubMed |
| Varicella-zoster virus infection triggering GD3 antibody-positive variant Guillain-Barré syndrome: a case report and literature review. | BMC Neurol | 2026 | 42098679 | PubTator, text mining | PubMed |
| Higher magnetic field NMR renders resolution enhancement on ganglioside GD3 catalyzed heterogeneous Aβ42 aggregates. | Solid State Nucl Magn Reson | 2026 | 42061286 | PubTator, text mining | PubMed |
| Suppression of Inflammatory Responses Through GD3 Synthase (GD3S) Silencing Mediated by TLR4 Signaling: In Vitro and In Silico Analysis. | Mol Neurobiol | 2026 | 41954870 | PubTator, text mining | PubMed |
| Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. | Oncoimmunology | 2026 | 41928453 | PubTator, text mining | PubMed |
1 to 10 of 1,950
See all 1,950 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/117189
GET https://conductscience.org/api/genes/v1/117189/grants?page=2